Paid Clinical Trials - 82,000 Members & Growing

  • Sponsored Links
  • About Us
  • Auto-Updates
  • FAQ's
  • Quick Start Guide
www.GlobalTestMarket.com

 

Find Paid Clinical Trials Join Paid Clinical Trials ...

PaidClinicalTrials.org is a registry of compensated and uncompensated, federally and privately supported clinical trials conducted in the United States and around the world. Here you will find information about a trial's purpose, who may participate, locations, and phone numbers.

 

Find Paid Clinical Trials Clinical Trial Seekers - PCT is a public service, sponsor supported, clinical trial database that may be accessed by the general public at no charge in accordance with our terms of service use.

Clinical trials are added and removed each day on a 30 day rotation. For accuracy - We only list clinical trials that have been reported to these government agencies in the last 30 days:

 

U.S. National Library of Medicine,
U.S. Department of Health & Human Services
U.S. National Institutes of health Services.







Paid Clinical Trials - Auto Update Service

If you would like to receive timely and important notifications about new clinical trials in your area please fill out this short form. There is never any cost for our notification services. We value your privacy, your email address and member information is NEVER shared!

*  Your Email Address:
*  Preferred Format:
    Title:
    First Name:
    Country:
    State (US):
    City (UK):
    Territory (AU):

Tips for Finding Clinical Trials

 

One of the toughest and most-time consuming parts for medical research staff conducting the clinical trials is actually finding volunteers willing to participate. Research staff are looking for you! There are numerous ways to identify clinical trials looking for healthy human volunteers.

 

Trials are actively conducted by hospitals, universities, foundations, and contract research organizations (CROs, firms that conduct studies for big pharmaceutical and biotechnology companies). According to CISCRP, nearly 40% of these clinical trials can be learned about through media such as tv, radio, or printed ads. While finding studies through tv and radio ads might be difficult, you can actively scour the wanted section of your local newspapers to find trials.

Most local research clinics run ads for volunteers in the local newspaper, employment papers, on TV, and on the radio. They also post ads on Craigslist and on their own websites. Call them up as soon as you see something of interest. If the study is no longer recruiting volunteers, they might enter you in there database for future study participation.

 

Look up local research clinics in your phone book and ask (a) if they have any studies openly recruiting healthy volunteers and (b) if you could be entered into their volunteer database.

College campuses and major universities with research hospitals are also great places to find clinical trial. Schools of medicine, dentistry, and nursing, along with departments of psychology, sociology, and communications, at local universities, are always looking for willing volunteers for their experiments. Perform an internet search for the hospitals, schools, and departments on nearby campuses, then look for any section concerning clinical trials or research volunteers.


When searching for clinical trials on our website you will click on a Clinical Trial Information sheet like this example. Find Paid Clinical Trials Example Information Sheet. The first thing you should do is to see if the clinical trial is right for you. You can do this by quickly scanning the headings of the information sheet. These headings are highlighted on the left by blue icons as follows:


  >> Status of the Clinical Trial (This will appear at the top in red or green)


Purpose - This will briefly let you know about the clinical trial and how it is conducted.


Eligibility - This tells you age, gender and health status information. If you do not meet these eligibility requirement you should move to another clinical trial.


Contacts and Locations - This will list the locations the clinical trial is being conducted and it will usually list the contact person to call. Note - Even if your location is not listed you should call the clinical trial investigator. Sometimes their locations have not been updated or they are willing to pay time and travel expenses.


More Information - This will often give alternative contact people and other pertinent information about the trial.

These headings appear on the left side of the information sheet and are fairly self explanatory. Doing this will help you to quickly evaluate if the clinical trial is right for you.

 


 

Paid Clinical Trials Searching Tips

 

Paid Clinical Trials Check the Conditions Category - If you only search the "Locations" directory you are missing out on a lot of clinical trials. Trials that are listed by "Condition" usually have multiple locations and can add new locations as the study moves forward.

 

Paid Clinical Trials Register Your Profile with us. - You can post your location and condition in our personal clinical trials directory for FREE. This helps the research recruiters find you when the right trial becomes available. Register for Clinical Trials Here.

 

Paid Clinical Trials Call the Clinical Trial Recruiters - At the bottom of all the information sheets you will see a "Contact Information" heading. Many clinical trials can be conducted in remote locations and the recruiters can help you.

 

Paid Clinical Trials Subscribe to our Auto Update Service - By subscribing to our Auto Update Service you will receive automated emails informing you when new trials have opened in your area.


Browse Locations ... United States» ... New York» ... Buffalo







  • Condition:   Pharmacokinetic Assessments in Healthy Volunteers
    Interventions:   Drug: PPI-668 tablet;   Drug: PPI-668 capsule
    Sponsor:   Presidio Pharmaceuticals, Inc.
    Recruiting - verified October 2014

  • Condition:   Patellar (or Kneecap) Instability and Mal-alignment
    Intervention:  
    Sponsors:   State University of New York at Buffalo;   Carestream Health, Inc.
    Not yet recruiting - verified October 2014

  • Condition:   Familial Amyloidotic Cardiomyopathy (FAC)
    Intervention:  
    Sponsor:   Alnylam Pharmaceuticals
    Recruiting - verified September 2014

  • Condition:   Hyperlipidemia
    Interventions:   Drug: Evacetrapib;   Drug: Atorvastatin;   Drug: Ezetimibe;   Drug: Placebo
    Sponsor:   Eli Lilly and Company
    Recruiting - verified October 2014

  • Condition:   Ischemic Stroke
    Interventions:   Biological: 3K3A-APC;   Drug: Placebo
    Sponsors:   ZZ Biotech, LLC;   National Institute of Neurological Disorders and Stroke (NINDS);   Cedars-Sinai Medical Center;   Massachusetts General Hospital;   University of Iowa
    Recruiting - verified October 2014

  • Conditions:   Wide Neck Bifurcation Intracranial Aneurysms;   Intracranial Aneurysms
    Intervention:   Device: WEB
    Sponsor:   Sequent Medical, Inc
    Recruiting - verified October 2014

  • Conditions:   Adult Alveolar Soft-part Sarcoma;   Adult Angiosarcoma;   Adult Epithelioid Sarcoma;   Adult Extraskeletal Chondrosarcoma;   Adult Extraskeletal Osteosarcoma;   Adult Fibrosarcoma;   Adult Leiomyosarcoma;   Adult Liposarcoma;   Adult Malignant Fibrous Histiocytoma;   Adult Malignant Mesenchymoma;   Adult Synovial Sarcoma;   Childhood Alveolar Soft-part Sarcoma;   Childhood Angiosarcoma;   Childhood Epithelioid Sarcoma;   Childhood Leiomyosarcoma;   Childhood Liposarcoma;   Childhood Malignant Mesenchymoma;   Childhood Synovial Sarcoma;   Nonmetastatic Childhood Soft Tissue Sarcoma;   Stage IB Adult Soft Tissue Sarcoma;   Stage IIB Adult Soft Tissue Sarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage IV Adult Soft Tissue Sarcoma
    Interventions:   Drug: pazopanib hydrochloride;   Drug: ifosfamide;   Drug: doxorubicin hydrochloride;   Radiation: radiation therapy;   Procedure: therapeutic conventional surgery;   Other: pharmacological study;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified July 2014

  • Condition:   Diabetes Mellitus, Type II
    Interventions:   Drug: Placebo;   Drug: PF-06291874;   Drug: PF-06291874;   Drug: PF-06291874;   Drug: PF-06291874
    Sponsor:   Pfizer
    Recruiting - verified October 2014

  • Conditions:   Recurrent Renal Cell Cancer;   Stage I Renal Cell Cancer;   Stage II Renal Cell Cancer
    Interventions:   Biological: renal cell carcinoma/CD40L RNA-transfected autologous dendritic cell vaccine AGS-003;   Procedure: therapeutic conventional surgery;   Other: laboratory biomarker analysis
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified October 2014

  • Conditions:   Urinary Tract Infection Complicated;   Acute Pyelonephritis;   Hospital Acquired Bacterial Pneumonia;   Ventilator-associated Bacterial Pneumonia;   Bacteremia
    Interventions:   Drug: Carbavance;   Drug: Best Available Therapy
    Sponsors:   Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company);   Department of Health and Human Services
    Recruiting - verified October 2014

  • Conditions:   Stage IA Fallopian Tube Cancer;   Stage IA Ovarian Epithelial Cancer;   Stage IA Primary Peritoneal Cavity Cancer;   Stage IB Fallopian Tube Cancer;   Stage IB Ovarian Epithelial Cancer;   Stage IB Primary Peritoneal Cavity Cancer;   Stage IC Fallopian Tube Cancer;   Stage IC Ovarian Epithelial Cancer;   Stage IC Primary Peritoneal Cavity Cancer;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIA Primary Peritoneal Cavity Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIB Primary Peritoneal Cavity Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Epithelial Cancer;   Stage IIC Primary Peritoneal Cavity Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Primary Peritoneal Cavity Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Primary Peritoneal Cavity Cancer
    Interventions:   Biological: DEC-205/NY-ESO-1 fusion protein CDX-1401;   Drug: poly ICLC;   Drug: IDO1 inhibitor INCB024360;   Other: pharmacological study;   Other: laboratory biomarker analysis
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified September 2014

  • Conditions:   Urinary Tract Infection Complicated;   Acute Pyelonephritis
    Interventions:   Drug: Carbavance;   Drug: Piperacillin/tazobactam;   Drug: Levofloxacin oral
    Sponsors:   Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company);   Department of Health and Human Services
    Recruiting - verified October 2014

  • Conditions:   Diabetic Nephropathy;   Diabetic Kidney Disease
    Interventions:   Drug: Pyridorin;   Drug: Placebo
    Sponsors:   NephroGenex, Inc.;   Collaborative Study Group (CSG);   Medpace, Inc.
    Recruiting - verified October 2014

  • Condition:   Moderate to Very Severe Chronic Obstructive Pulmonary Disease
    Interventions:   Drug: Benralizumab Arm A;   Drug: Benralizumab Arm B;   Drug: Placebo
    Sponsors:   AstraZeneca;   MedImmune LLC
    Recruiting - verified October 2014

  • Condition:   Infection, Human Immunodeficiency Virus
    Interventions:   Drug: ABC/DTG/3TC FDC;   Drug: Ongoing cART regimen
    Sponsors:   ViiV Healthcare;   PPD;   GlaxoSmithKline
    Recruiting - verified October 2014

  • Condition:   HIV Infection
    Interventions:   Drug: Reformulated Raltegravir;   Drug: Raltegravir;   Drug: TRUVADA™;   Drug: Placebo to Reformulated Raltegravir;   Drug: Placebo to Raltegravir
    Sponsor:   Merck Sharp & Dohme Corp.
    Recruiting - verified October 2014

  • Conditions:   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage I Squamous Cell Carcinoma of the Oropharynx;   Stage I Verrucous Carcinoma of the Oral Cavity;   Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage II Squamous Cell Carcinoma of the Oropharynx;   Stage II Verrucous Carcinoma of the Oral Cavity;   Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage III Squamous Cell Carcinoma of the Oropharynx;   Stage III Verrucous Carcinoma of the Oral Cavity;   Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVA Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Verrucous Carcinoma of the Oral Cavity;   Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVB Squamous Cell Carcinoma of the Oropharynx;   Stage IVB Verrucous Carcinoma of the Oral Cavity;   Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVC Squamous Cell Carcinoma of the Oropharynx;   Stage IVC Verrucous Carcinoma of the Oral Cavity
    Interventions:   Drug: HPPH;   Device: Light Infusion Therapy™;   Procedure: therapeutic conventional surgery
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
    Not yet recruiting - verified October 2014

  • Conditions:   Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN);   Acute Myeloid Leukemia
    Intervention:   Drug: SL-401
    Sponsors:   Stemline Therapeutics, Inc.;   The Leukemia and Lymphoma Society
    Recruiting - verified October 2014

  • Condition:   Myasthenia Gravis
    Interventions:   Drug: Rituximab;   Drug: Placebo
    Sponsor:   Yale University
    Recruiting - verified October 2014

  • Condition:   Chronic Hepatitis C
    Interventions:   Drug: MK-5172 100 mg/MK-8742 50 mg FDC tablets;   Drug: Placebo to MK-5172 100 mg/MK-8742 50 mg FDC tablets
    Sponsor:   Merck Sharp & Dohme Corp.
    Recruiting - verified October 2014

  • Condition:   Hepatitis C Virus
    Intervention:   Drug: No intervention
    Sponsor:   Janssen Scientific Affairs, LLC
    Recruiting - verified October 2014

  • Condition:   Relapsed or Refractory Multiple Myeloma
    Intervention:   Biological: ALT-803
    Sponsors:   Altor Bioscience Corporation;   National Cancer Institute (NCI)
    Recruiting - verified October 2014

  • Conditions:   Colorectal Cancer;   Healthy, no Evidence of Disease
    Interventions:   Behavioral: behavioral intervention;   Behavioral: behavioral intervention
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified September 2014

  • Condition:   Chronic Myeloid Leukemia
    Intervention:   Drug: Omacetaxine mepesuccinate
    Sponsors:   Teva Branded Pharmaceutical Products, R&D Inc.;   Teva Pharmaceutical Industries
    Recruiting - verified September 2014

  • Condition:   Brain Ischemia
    Interventions:   Drug: alteplase [Activase];   Drug: alteplase placebo;   Drug: aspirin;   Drug: aspirin placebo
    Sponsor:   Genentech, Inc.
    Recruiting - verified October 2014

  • Conditions:   Acute Myeloid Leukemia (AML);   Acute Lymphocytic Leukemia (ALL)
    Intervention:   Drug: CB-839
    Sponsor:   Calithera Biosciences, Inc
    Recruiting - verified September 2014

  • Conditions:   Diabetes Mellitus, Type 2;   Diabetic Nephropathies
    Interventions:   Drug: Canagliflozin;   Drug: Placebo
    Sponsors:   Janssen Research & Development, LLC;   The George Institute for Global Health, Australia
    Recruiting - verified October 2014

  • Conditions:   Anemia;   Renal Insufficiency, Chronic
    Interventions:   Drug: Molidustat (BAY85-3934);   Biological: Epoetin alfa/beta
    Sponsor:   Bayer
    Recruiting - verified September 2014

  • Conditions:   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
    Interventions:   Drug: dovitinib lactate;   Drug: gemcitabine hydrochloride;   Drug: paclitaxel albumin-stabilized nanoparticle formulation;   Other: pharmacological study;   Other: laboratory biomarker analysis
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI);   Novartis
    Not yet recruiting - verified October 2014

  • Conditions:   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Primary Peritoneal Cavity Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Primary Peritoneal Cavity Cancer
    Interventions:   Drug: IDO1 inhibitor INCB024360;   Procedure: therapeutic conventional surgery;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified June 2014

  • Condition:   Stage IV or Recurrent Non-Small Cell Lung Cancer
    Interventions:   Biological: Nivolumab;   Drug: Gemcitabine;   Drug: Cisplatin;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Pemetrexed
    Sponsor:   Bristol-Myers Squibb
    Recruiting - verified May 2014

  • Condition:   AML
    Interventions:   Drug: Quizartinib;   Drug: Salvage Chemotherapy
    Sponsor:   Ambit Biosciences Corporation
    Recruiting - verified October 2014

  • Conditions:   Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome;   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
    Interventions:   Drug: cytarabine;   Drug: omacetaxine mepesuccinate;   Drug: decitabine;   Other: laboratory biomarker analysis
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified October 2014

  • Condition:   Pneumonia
    Interventions:   Drug: TR-701 FA IV;   Drug: Linezolid
    Sponsor:   Cubist Pharmaceuticals
    Recruiting - verified September 2014

  • Condition:   Non-Small Cell Lung Cancer
    Interventions:   Drug: MPDL3280A;   Drug: docetaxel
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified October 2014

  • Condition:   Diabetes
    Intervention:  
    Sponsor:   Medtronic Diabetes
    Recruiting - verified September 2014

  • Condition:   Clostridium Difficile Associated Diarrhea
    Interventions:   Drug: Cadazolid;   Drug: vancomycin
    Sponsor:   Actelion
    Recruiting - verified September 2014

  • Conditions:   Anemia;   Renal Insufficiency, Chronic
    Interventions:   Drug: Molidustat (BAY 85-3934);   Biological: Epoetin alfa/beta
    Sponsor:   Bayer
    Recruiting - verified September 2014

  • Condition:   Kidney Transplantation Cytomegalovirus (CMV) Negative Recipients
    Interventions:   Biological: ASP0113;   Drug: Placebo
    Sponsors:   Astellas Pharma Global Development, Inc.;   Vical;   Astellas Pharma Inc
    Recruiting - verified September 2014

  • Conditions:   Pancreatic Neoplasms;   Digestive System Neoplasms;   Neoplasms by Site;   Neoplasms;   Endocrine Gland Neoplasms;   Pancreatic Diseases;   Digestive System Diseases;   Endocrine System Diseases;   Gemcitabine;   Antimetabolites, Antineoplastic
    Interventions:   Drug: nab-Paclitaxel 125 mg/m2;   Drug: gemcitabine 1000 mg/m2;   Drug: gemcitabine 1000 mg/m2
    Sponsor:   Celgene Corporation
    Recruiting - verified October 2014

  • Conditions:   Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Male Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer
    Interventions:   Drug: trametinib;   Drug: Akt inhibitor GSK2141795;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified July 2014

  • Condition:   Heart Failure
    Interventions:   Drug: Vericiguat (BAY1021189) (1.25 mg);   Drug: Vericiguat (BAY1021189) (5 mg);   Drug: Placebo
    Sponsor:   Bayer
    Recruiting - verified October 2014

  • Condition:   Heart Failure
    Interventions:   Drug: Vericiguat (BAY1021189) (1.25 mg);   Drug: Vericiguat (BAY1021189) (5 mg);   Drug: Placebo
    Sponsor:   Bayer
    Recruiting - verified October 2014

  • Condition:   Colorectal Neoplasms
    Interventions:   Drug: Regorafenib (Stivarga, BAY73-4506);   Drug: Placebo
    Sponsor:   Bayer
    Recruiting - verified October 2014

  • Conditions:   Adult Primary Liver Cancer;   Breast Cancer;   Colon Cancer;   Head and Neck Cancer;   Kidney Tumor;   Lung Cancer;   Malignant Neoplasm;   Melanoma;   Ovarian Neoplasm;   Soft Tissue Sarcoma
    Interventions:   Procedure: hyperthermia treatment;   Procedure: hyperthermia treatment;   Other: laboratory biomarker analysis
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI);   Braun Foundation
    Recruiting - verified October 2014

  • Condition:   Multiple Sclerosis
    Interventions:   Drug: Interferon beta-1a i.m. injections;   Drug: Fingolimod oral capsules;   Drug: Placebo oral capsule;   Drug: Placebo i.m. injection
    Sponsors:   Novartis Pharmaceuticals;   Novartis
    Recruiting - verified October 2014

  • Conditions:   Heart Failure;   Coronary Artery Disease
    Interventions:   Drug: Rivaroxaban;   Drug: Placebo;   Other: Standard of care for heart failure and coronary artery disease
    Sponsor:   Janssen Research & Development, LLC
    Recruiting - verified October 2014

  • Conditions:   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma
    Interventions:   Drug: lenalidomide;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: vincristine sulfate;   Drug: prednisone;   Other: laboratory biomarker analysis;   Procedure: positron emission tomography
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2014

  • Condition:   Neoplasms
    Intervention:   Drug: Regorafenib (Stivarga, BAY73-4506)
    Sponsor:   Bayer
    Recruiting - verified October 2014

  • Conditions:   Newly Diagnosed;   Advanced Ovarian Cancer;   FIGO Stage III-IV;   BRCA Mutation;   Complete Response;   Partial Response;   First Line Platinum Chemotherapy
    Intervention:   Drug: Olaparib 300mg tablets
    Sponsors:   AstraZeneca;   Gynecologic Oncology Group (GOG);   Myriad Genetics - BRACAnalysis test for FDA Premarket Approval (PMA)
    Recruiting - verified October 2014

  • Condition:   Cardiovascular Disease
    Intervention:   Behavioral: Problem Solving
    Sponsor:   Department of Veterans Affairs
    Recruiting - verified September 2014

  • Conditions:   Clear Cell Renal Cell Carcinoma;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer
    Interventions:   Drug: cabozantinib-s-malate;   Drug: sunitinib malate;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified October 2014

  • Conditions:   Adult Primary Hepatocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Localized Unresectable Adult Primary Liver Cancer;   Recurrent Adult Primary Liver Cancer;   Stage C Adult Primary Liver Cancer (BCLC);   Stage D Adult Primary Liver Cancer (BCLC)
    Interventions:   Drug: tivozanib;   Other: pharmacological study;   Other: laboratory biomarker analysis
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified October 2014

  • Conditions:   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Anemia With Excess Blasts in Transformation;   Untreated Adult Acute Myeloid Leukemia
    Interventions:   Biological: DEC-205/NY-ESO-1 fusion protein CDX-1401;   Drug: poly ICLC;   Drug: decitabine;   Other: laboratory biomarker analysis
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified September 2014

  • Condition:   Kidney Transplantation
    Interventions:   Drug: Belatacept;   Drug: Tacrolimus;   Drug: Cyclosporine
    Sponsor:   Bristol-Myers Squibb
    Recruiting - verified October 2014

  • Condition:   Hypercholesterolemia
    Interventions:   Biological: Evolocumab (AMG 145);   Other: Placebo
    Sponsor:   Amgen
    Recruiting - verified October 2014

  • Conditions:   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
    Interventions:   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: idarubicin hydrochloride;   Drug: vorinostat;   Procedure: allogeneic hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified September 2014

  • Condition:   Pneumonia, Bacterial
    Interventions:   Drug: Amikacin Inhalation Solution (BAY41-6551);   Drug: Aerosolized Placebo
    Sponsors:   Bayer;   Nektar Therapeutics
    Recruiting - verified September 2014

  • Conditions:   Bladder Cancer;   Urothelial Carcinoma
    Interventions:   Drug: OGX-427;   Drug: Docetaxel
    Sponsors:   Hoosier Cancer Research Network;   OncoGenex Technologies
    Recruiting - verified October 2014

  • Condition:   Recurrent Neuroblastoma
    Interventions:   Drug: temozolomide;   Drug: irinotecan hydrochloride;   Drug: temsirolimus;   Biological: dinutuximab;   Biological: sargramostim;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified August 2014

  • Conditions:   Recurrent Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
    Interventions:   Biological: recombinant hsp110-gp100 chaperone complex vaccine;   Other: laboratory biomarker analysis
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified October 2014

  • Conditions:   Diabetes Mellitus, Non-Insulin-Dependent;   High Risk for Cardiovascular Event
    Interventions:   Drug: Dapagliflozin 10 mg;   Drug: Placebo tablet
    Sponsors:   AstraZeneca;   Bristol-Myers Squibb;   The TIMI Study Group;   Hadassah Medical Organization
    Recruiting - verified September 2014

  • Condition:   Nausea
    Interventions:   Device: Acupressure bands;   Other: Version 1 handout;   Behavioral: Version 1 MP3;   Other: Version 2 handout;   Behavioral: Version 2 MP3
    Sponsors:   University of Rochester;   National Center for Complementary and Alternative Medicine (NCCAM)
    Recruiting - verified October 2014

  • Condition:   Lymphocytic Leukemia, Chronic
    Interventions:   Drug: GDC-0199 (ABT-199);   Drug: Obinutuzumab
    Sponsor:   Genentech, Inc.
    Recruiting - verified October 2014

  • Condition:   Carcinoid Syndrome
    Interventions:   Drug: Telotristat etiprate tablets (250 mg);   Drug: Placebo tablets
    Sponsor:   Lexicon Pharmaceuticals
    Recruiting - verified October 2014

  • Condition:   Acute Coronary Syndrome
    Interventions:   Drug: alirocumab SAR236553 (REGN727);   Other: placebo
    Sponsors:   Sanofi;   Regeneron Pharmaceuticals
    Recruiting - verified October 2014

  • Condition:   Peripheral Vascular Surgical Bleeding
    Interventions:   Biological: Fibrin Sealant Grifols;   Procedure: Manual Compression
    Sponsors:   Instituto Grifols, S.A.;   Grifols Biologicals Inc.
    Recruiting - verified October 2014

  • Condition:   Management of Anemia in Chronic Kidney Disease Patients Not on Dialysis.
    Intervention:   Biological: Darbepoetin alfa
    Sponsor:   Amgen
    Recruiting - verified October 2014

  • Conditions:   Mucinous Adenocarcinoma of the Colon;   Mucinous Adenocarcinoma of the Rectum;   Signet Ring Adenocarcinoma of the Colon;   Signet Ring Adenocarcinoma of the Rectum;   Stage IV Colon Cancer;   Stage IV Rectal Cancer
    Interventions:   Biological: aflibercept;   Drug: oxaliplatin;   Drug: leucovorin;   Drug: fluorouracil;   Other: Correlative Studies;   Procedure: DCE MRI;   Radiation: f18FDG-PET;   Procedure: PET (positron emission tomography)
    Sponsors:   Richard Goldberg;   Sanofi;   Ohio State University Comprehensive Cancer Center
    Recruiting - verified September 2014

  • Conditions:   Adult Acute Basophilic Leukemia;   Adult Acute Eosinophilic Leukemia;   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myelomonocytic Leukemia (M4);   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
    Interventions:   Drug: daunorubicin hydrochloride;   Drug: cytarabine;   Drug: decitabine;   Other: laboratory biomarker analysis;   Other: pharmacological study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified June 2014

  • Condition:   Clostridium Difficile Infection
    Interventions:   Drug: CB-183,315;   Drug: oral vancomycin
    Sponsor:   Cubist Pharmaceuticals
    Recruiting - verified October 2014

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Grade III Lymphomatoid Granulomatosis;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Aplastic Anemia;   Burkitt Lymphoma;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Grade III Lymphomatoid Granulomatosis;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Congenital Amegakaryocytic Thrombocytopenia;   Diamond-Blackfan Anemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Juvenile Myelomonocytic Leukemia;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Paroxysmal Nocturnal Hemoglobinuria;   Peripheral T-cell Lymphoma;   Polycythemia Vera;   Post-transplant Lymphoproliferative Disorder;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Secondary Myelofibrosis;   Severe Combined Immunodeficiency;   Severe Congenital Neutropenia;   Shwachman-Diamond Syndrome;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Waldenstrom Macroglobulinemia;   Wiskott-Aldrich Syndrome
    Interventions:   Drug: fludarabine phosphate;   Drug: melphalan;   Radiation: total-body irradiation;   Drug: tacrolimus;   Drug: mycophenolate mofetil;   Drug: methotrexate;   Other: laboratory biomarker analysis;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation
    Sponsor:   Roswell Park Cancer Institute
    Recruiting - verified October 2014

  • Conditions:   Adult Anaplastic Astrocytoma;   Adult Anaplastic Oligodendroglioma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Mixed Glioma;   Adult Primary Hepatocellular Carcinoma;   Chondrosarcoma;   Clear Cell Sarcoma of the Kidney;   Conjunctival Kaposi Sarcoma;   Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   Hormone-resistant Prostate Cancer;   Limited Stage Small Cell Lung Cancer;   Localized Resectable Adult Primary Liver Cancer;   Male Breast Cancer;   Mast Cell Sarcoma;   Ovarian Sarcoma;   Recurrent Adult Brain Tumor;   Recurrent Adult Primary Liver Cancer;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Bladder Cancer;   Recurrent Breast Cancer;   Recurrent Colon Cancer;   Recurrent Esophageal Cancer;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Gastric Cancer;   Recurrent Kaposi Sarcoma;   Recurrent Melanoma;   Recurrent Non-small Cell Lung Cancer;   Recurrent Osteosarcoma;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Prostate Cancer;   Recurrent Rectal Cancer;   Recurrent Renal Cell Cancer;   Recurrent Small Cell Lung Cancer;   Recurrent Uterine Sarcoma;   Small Intestine Leiomyosarcoma;   Stage I Colon Cancer;   Stage I Rectal Cancer;   Stage I Uterine Sarcoma;   Stage IA Breast Cancer;   Stage IA Gastric Cancer;   Stage IA Ovarian Epithelial Cancer;   Stage IA Ovarian Germ Cell Tumor;   Stage IB Breast Cancer;   Stage IB Gastric Cancer;   Stage IB Ovarian Epithelial Cancer;   Stage IB Ovarian Germ Cell Tumor;   Stage IC Ovarian Epithelial Cancer;   Stage IC Ovarian Germ Cell Tumor;   Stage II Breast Cancer;   Stage II Uterine Sarcoma;   Stage IIA Colon Cancer;   Stage IIA Gastric Cancer;   Stage IIA Non-small Cell Lung Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIA Ovarian Germ Cell Tumor;   Stage IIA Rectal Cancer;   Stage IIB Colon Cancer;   Stage IIB Esophageal Cancer;   Stage IIB Gastric Cancer;   Stage IIB Melanoma;   Stage IIB Non-small Cell Lung Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIB Ovarian Germ Cell Tumor;   Stage IIB Rectal Cancer;   Stage IIC Colon Cancer;   Stage IIC Melanoma;   Stage IIC Ovarian Epithelial Cancer;   Stage IIC Ovarian Germ Cell Tumor;   Stage IIC Rectal Cancer;   Stage III Uterine Sarcoma;   Stage IIIA Breast Cancer;   Stage IIIA Colon Cancer;   Stage IIIA Esophageal Cancer;   Stage IIIA Gastric Cancer;   Stage IIIA Melanoma;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Ovarian Germ Cell Tumor;   Stage IIIA Rectal Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Esophageal Cancer;   Stage IIIB Gastric Cancer;   Stage IIIB Melanoma;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Ovarian Germ Cell Tumor;   Stage IIIB Rectal Cancer;   Stage IIIC Breast Cancer;   Stage IIIC Colon Cancer;   Stage IIIC Esophageal Cancer;   Stage IIIC Gastric Cancer;   Stage IIIC Melanoma;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Ovarian Germ Cell Tumor;   Stage IIIC Rectal Cancer;   Stage IV Bladder Cancer;   Stage IV Esophageal Cancer;   Stage IV Gastric Cancer;   Stage IV Melanoma;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Prostate Cancer;   Stage IV Renal Cell Cancer;   Stage IV Uterine Sarcoma;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
    Interventions:   Biological: DEC-205-NY-ESO-1 fusion protein vaccine;   Drug: sirolimus;   Other: laboratory biomarker analysis;   Other: pharmacological study
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified September 2014

  • Condition:   Non-Small Cell Lung Cancer
    Interventions:   Drug: GDC-0941;   Drug: Placebo;   Drug: bevacizumab;   Drug: carboplatin;   Drug: paclitaxel
    Sponsor:   Genentech, Inc.
    Recruiting - verified October 2014

  • Conditions:   Stroke;   Atrial Fibrillation
    Intervention:  
    Sponsor:   Boehringer Ingelheim
    Recruiting - verified October 2014

  • Condition:   Diabetes Mellitus, Type 2
    Interventions:   Drug: Placebo matching with Saxagliptin;   Drug: Metformin IR;   Drug: Metformin XR;   Drug: Saxagliptin;   Drug: Saxagliptin
    Sponsors:   Bristol-Myers Squibb;   AstraZeneca
    Recruiting - verified April 2014

  • Condition:   Pediatric Multiple Sclerosis
    Intervention:  
    Sponsors:   University of California, San Francisco;   Stony Brook University;   Massachusetts General Hospital;   State University of New York at Buffalo;   University of Alabama at Birmingham;   Mayo Clinic;   Children's Hospital Philadelphia;   Children's Hospital Boston;   Texas Children's Hospital;   Loma Linda University;   Children's Hospital Colorado;   University of Texas;   Ann & Robert H Lurie Children's Hospital of Chicago;   Washington University School of Medicine;   Children's National Med Center;   Primary Children's Hospital
    Recruiting - verified October 2014

  • Condition:   Major Depressive Disorder
    Interventions:   Drug: Desvenlafaxine Succinate Sustained-Release;   Drug: Desvenlafaxine Succinate Sustained-Release;   Drug: Placebo
    Sponsor:   Pfizer
    Recruiting - verified October 2014

  • Condition:   Major Depressive Disorder
    Intervention:   Drug: DVS SR
    Sponsor:   Pfizer
    Recruiting - verified October 2014

  • Conditions:   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Childhood Acute Erythroleukemia (M6);   Childhood Acute Megakaryocytic Leukemia (M7);   Childhood Acute Monoblastic Leukemia (M5a);   Childhood Acute Monocytic Leukemia (M5b);   Childhood Acute Myeloblastic Leukemia With Maturation (M2);   Childhood Acute Myeloblastic Leukemia Without Maturation (M1);   Childhood Acute Myelomonocytic Leukemia (M4);   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
    Interventions:   Drug: asparaginase;   Drug: daunorubicin hydrochloride;   Drug: mitoxantrone hydrochloride;   Drug: sorafenib tosylate;   Drug: cytarabine;   Drug: etoposide;   Drug: bortezomib;   Other: pharmacological study;   Other: laboratory biomarker analysis;   Other: questionnaire administration;   Other: quality-of-life assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified October 2014

  • Conditions:   Hematologic Malignancies;   Certain:;   Inherited Disorders of Metabolism;   Inherited Abnormalities of Erythrocyte Differentiation or Function;   Inherited Abnormalities of Platelets;   Disorders of the Immune System;   Histiocytic Disorders;   X-linked Adrenoleukodystrophy;   Primary Immunodeficiency Diseases;   Bone Marrow Failure;   Beta-thalassemia
    Intervention:   Drug: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
    Sponsors:   Center for International Blood and Marrow Transplant Research;   National Marrow Donor Program
    Recruiting - verified October 2014

  • Condition:   Delayed Graft Function
    Intervention:   Drug: BB3
    Sponsors:   Angion Biomedica Corp;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    Recruiting - verified October 2014

  • Conditions:   Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   HER2-positive Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer
    Interventions:   Drug: doxorubicin hydrochloride;   Drug: docetaxel;   Drug: cyclophosphamide;   Biological: trastuzumab;   Drug: paclitaxel;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified July 2014

  • Conditions:   Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
    Interventions:   Drug: systemic chemotherapy;   Drug: tamoxifen citrate;   Drug: anastrozole;   Drug: exemestane;   Drug: letrozole;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified September 2014

  • Conditions:   Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia
    Interventions:   Biological: alemtuzumab;   Drug: dasatinib;   Drug: daunorubicin hydrochloride;   Drug: fludarabine phosphate;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: in vitro-treated peripheral blood stem cell transplantation;   Drug: dexamethasone;   Drug: cyclophosphamide;   Biological: filgrastim;   Biological: pegfilgrastim;   Drug: methotrexate;   Drug: leucovorin calcium;   Drug: melphalan;   Drug: tacrolimus;   Drug: etoposide phosphate;   Drug: cytarabine;   Drug: mercaptopurine;   Drug: vincristine sulfate;   Other: pharmacological study;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified July 2014

  • Conditions:   Advanced Solid Tumors;   Advanced Recurrent Ovarian Tumors
    Interventions:   Drug: MEDI3617;   Drug: MEDI3617 + Bev Q3W Dose Escalation;   Drug: MEDI3617 + Bev Q2W Dose Escalation;   Drug: Optional Dose Expansion;   Drug: MEDI3617 + Weekly Pax Dose Escalation;   Drug: MEDI3617 + Pax & Carbo Q3W Dos Esc;   Drug: MEDI3617 + Gem & Carbo Q3W Dos Esc;   Drug: Advanced Recurrent Ovarian Tumors
    Sponsor:   MedImmune LLC
    Recruiting - verified September 2014

  • Conditions:   Acute Myocardial Infarction;   Congestive Heart Failure;   ST-Elevation Myocardial Infarction
    Interventions:   Device: Sodium Alginate and Calcium Gluconate;   Device: Saline Solution
    Sponsors:   Bellerophon BCM LLC;   Bellerophon
    Recruiting - verified October 2014

  • Conditions:   Prostate Neoplasms;   Genital Neoplasms, Male;   Urogenital Neoplasms;   Genital Diseases, Male
    Intervention:   Drug: Abiraterone Acetate
    Sponsor:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
    Recruiting - verified October 2014

  • Conditions:   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Pineoblastoma;   Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor
    Interventions:   Drug: temozolomide;   Drug: irinotecan hydrochloride;   Biological: bevacizumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified September 2014

  • Condition:   Type 2 Diabetes
    Interventions:   Drug: Saxagliptin;   Drug: Placebo (Saxagliptin);   Drug: Metformin IR;   Drug: Placebo (Metformin);   Drug: Metformin (Active Rescue)
    Sponsors:   Bristol-Myers Squibb;   AstraZeneca
    Recruiting - verified April 2014

  • Conditions:   Adult Primary Hepatocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Localized Unresectable Adult Primary Liver Cancer;   Recurrent Adult Primary Liver Cancer;   Stage C Adult Primary Liver Cancer (BCLC);   Stage D Adult Primary Liver Cancer (BCLC)
    Interventions:   Drug: doxorubicin hydrochloride;   Drug: sorafenib tosylate;   Other: laboratory biomarker analysis;   Other: pharmacological study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified September 2014

  • Conditions:   B-cell Chronic Lymphocytic Leukemia;   Refractory Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia
    Interventions:   Drug: lenalidomide;   Drug: R-(-)-gossypol acetic acid
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting - verified October 2014

  • Conditions:   Childhood Hepatoblastoma;   Stage I Childhood Liver Cancer;   Stage II Childhood Liver Cancer;   Stage III Childhood Liver Cancer;   Stage IV Childhood Liver Cancer
    Interventions:   Procedure: therapeutic conventional surgery;   Drug: cisplatin;   Drug: fluorouracil;   Drug: vincristine sulfate;   Drug: doxorubicin hydrochloride;   Drug: irinotecan hydrochloride;   Drug: temsirolimus;   Procedure: liver transplantation;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified October 2014

  • Conditions:   Distal Urethral Cancer;   Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter;   Proximal Urethral Cancer;   Recurrent Bladder Cancer;   Recurrent Prostate Cancer;   Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter;   Recurrent Urethral Cancer;   Regional Transitional Cell Cancer of the Renal Pelvis and Ureter;   Stage IV Bladder Cancer;   Stage IV Prostate Cancer;   Stage IV Urethral Cancer;   Transitional Cell Carcinoma of the Bladder;   Ureter Cancer;   Urethral Cancer Associated With Invasive Bladder Cancer
    Interventions:   Drug: gemcitabine hydrochloride;   Drug: cisplatin;   Other: placebo;   Biological: bevacizumab;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified August 2014

  • Conditions:   Diffuse Hyperplastic Perilobar Nephroblastomatosis;   Stage I Wilms Tumor;   Stage II Wilms Tumor;   Stage III Wilms Tumor;   Stage IV Wilms Tumor;   Stage V Wilms Tumor
    Interventions:   Drug: doxorubicin hydrochloride;   Procedure: therapeutic conventional surgery;   Biological: dactinomycin;   Drug: cyclophosphamide;   Drug: carboplatin;   Drug: etoposide phosphate;   Drug: vincristine sulfate;   Procedure: adjuvant therapy;   Procedure: neoadjuvant therapy
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified October 2014

  • Conditions:   Neoplasms;   Lymphomas
    Intervention:   Procedure: Biopsy
    Sponsors:   National Cancer Institute (NCI);   National Institutes of Health Clinical Center (CC)
    Recruiting - verified April 2014

  • Conditions:   Non-Small Cell Lung Cancer;   Anemia;   Cancer;   Lung Cancer
    Interventions:   Drug: darbepoetin alfa 500 mcg Q3W;   Drug: placebo
    Sponsor:   Amgen
    Recruiting - verified October 2014

  • Condition:   Lung Cancer
    Intervention:   Radiation: stereotactic body radiation therapy
    Sponsor:   Roswell Park Cancer Institute
    Recruiting - verified October 2014

  • Condition:   Ductal Breast Carcinoma in Situ
    Interventions:   Biological: trastuzumab;   Radiation: whole breast irradiation;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified June 2014

  • Conditions:   Crohn's Disease;   Ulcerative Colitis;   Indeterminate Colitis;   Inflammatory Bowel Diseases
    Interventions:   Biological: Anti TNF therapy including infliximab;   Drug: No Biologics
    Sponsor:   Janssen Biotech, Inc.
    Recruiting - verified October 2014

  • Conditions:   Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Salivary Gland Cancer;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Verrucous Carcinoma of the Larynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Salivary Gland Squamous Cell Carcinoma;   Stage IV Salivary Gland Cancer;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IVA Salivary Gland Cancer;   Stage IVA Squamous Cell Carcinoma of the Larynx;   Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVA Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Verrucous Carcinoma of the Larynx;   Stage IVA Verrucous Carcinoma of the Oral Cavity;   Stage IVB Salivary Gland Cancer;   Stage IVB Squamous Cell Carcinoma of the Larynx;   Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVB Squamous Cell Carcinoma of the Oropharynx;   Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Verrucous Carcinoma of the Larynx;   Stage IVB Verrucous Carcinoma of the Oral Cavity;   Stage IVC Salivary Gland Cancer;   Stage IVC Squamous Cell Carcinoma of the Larynx;   Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVC Squamous Cell Carcinoma of the Oropharynx;   Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Verrucous Carcinoma of the Larynx;   Stage IVC Verrucous Carcinoma of the Oral Cavity;   Tongue Cancer;   Untreated Metastatic Squamous Neck Cancer With Occult Primary
    Interventions:   Drug: docetaxel;   Drug: cisplatin;   Drug: carboplatin;   Drug: fluorouracil;   Biological: bevacizumab;   Other: laboratory biomarker analysis;   Other: cytology specimen collection procedure
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified August 2014

  • Conditions:   Brenner Tumor;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer
    Interventions:   Drug: paclitaxel;   Drug: docetaxel;   Drug: carboplatin;   Biological: bevacizumab;   Drug: gemcitabine hydrochloride;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified October 2014

  • Condition:   Arthritis, Rheumatoid
    Interventions:   Drug: CP-690,550;   Drug: CP-690,550
    Sponsor:   Pfizer
    Recruiting - verified October 2014

  • Conditions:   Mycoses;   Candidiasis, Invasive;   Candidemia
    Interventions:   Drug: Isavuconazole;   Drug: Caspofungin;   Drug: Voriconazole
    Sponsors:   Astellas Pharma Inc;   Basilea Pharmaceutica
    Recruiting - verified September 2014

  • Condition:   Epilepsies, Partial
    Interventions:   Drug: Lyrica (pregabalin);   Drug: placebo
    Sponsor:   Pfizer
    Recruiting - verified October 2014

  • Conditions:   Acute Leukemia;   Acute Lymphoblastic Leukemia;   Myelodysplastic Syndrome;   Multiple Myeloma
    Intervention:   Genetic: cytogenetic analysis
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting - verified October 2014

  • Conditions:   Disseminated Neuroblastoma;   Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Regional Neuroblastoma;   Stage 4S Neuroblastoma
    Interventions:   Drug: isotretinoin;   Biological: sargramostim;   Biological: dinutuximab;   Biological: aldesleukin;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment;   Other: pharmacological study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified September 2014

PaidClinicalTrials.orgPaidClinicalTrials.org